# RAS mutation associated with short surgically controllable period in colorectal liver metastases: a retrospective study

**Authors:** Sono Ito, Takeshi Takamoto, Satoshi Nara, Daisuke Ban, Takahiro Mizui, Hiroshi Nagata, Yasuyuki Takamizawa, Konosuke Moritani, Shunsuke Tsukamoto, Yukihide Kanemitsu, Yusuke Kinugasa, Minoru Esaki

PMC · DOI: 10.1186/s12957-024-03529-9 · World Journal of Surgical Oncology · 2024-09-12

## TL;DR

This study finds that colorectal liver metastases with RAS mutations have shorter survival and shorter surgically controllable periods compared to those without mutations.

## Contribution

The study identifies RAS mutation as an independent predictor of shorter surgically controllable period in colorectal liver metastases.

## Key findings

- RAS-mutant patients had significantly worse surgically controllable period compared to wild-type patients.
- RAS mutation was an independent risk factor for less than 1 year of surgically controllable period.

## Abstract

The prognostic implications of the RAS status in colorectal cancer liver metastasis (CRLM) remain unclear. This study investigated the prognostic significance of RAS status after curative hepatectomy, focusing on surgical controllability.

This retrospective study included liver-only CRLM patients who underwent the first hepatectomy between 2015 and 2022 at the National Cancer Center Hospital. Recurrence-free survival (RFS), surgically controllable period (SCP), and overall survival (OS) were compared between RAS wild-type (RAS-wt) and mutant (RAS-mt) patients. Multivariate analyses were conducted to identify independent prognostic factors for each outcome and independent risk factors for less than 1 year SCP.

A total of 150 patients were evaluated, comprising 63 patients with RAS-mt status. There was no significant difference in RFS between RAS-mt and RAS-wt (7.00 vs. 8.03 months, p = 0.48). RAS-mt patients exhibited worse SCP (11.80 vs.21.13 months, p < 0.001) and OS (44.03 vs. 70.03 months, p < 0.001) compared to RAS-wt. Multivariate analysis identified RAS-mt as an independent prognostic factor for both OS (hazard ratio [HR]: 3.37, p < 0.001) and SCP (HR: 2.20, p < 0.001), and as an independent risk factor for less than 1 year of SCP (odds ratio, 2.31; p = 0.03).

CRLM with RAS mutations should be considered for strict surgical indications with preoperative chemotherapy and thorough examination, considering the possibility of short SCP.

The online version contains supplementary material available at 10.1186/s12957-024-03529-9.

## Linked entities

- **Genes:** ras (resistance to audiogenic seizures) [NCBI Gene 19412]
- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Diseases:** colorectal liver metastases (MESH:D009362), CRLM (MESH:D015179), Cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11391794/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11391794/full.md

---
Source: https://tomesphere.com/paper/PMC11391794